• Immuneering will present new preclinical atebimetinib combination data at the EORTC-NCI-AACR symposium, scheduled for November 17-19, 2026.
• Pancreatic cancer findings support combinations with targeted therapies; results will feature in a November 19 poster spotlight.
• Anaplastic thyroid cancer findings support combining atebimetinib with chemotherapy; presentation is scheduled for November 18.
• Phase 2 results presented at ASCO in June showed promising survival outcomes with atebimetinib plus chemotherapy in first-line pancreatic cancer.
• Atebimetinib is currently being evaluated in the Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040730PRIMZONEFULLFEED9869952) on November 04, 2026, and is solely responsible for the information contained therein.